{
    "root": "126a781e-e59f-4108-b897-362759588bf6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KADCYLA",
    "value": "20250519",
    "ingredients": [
        {
            "name": "TRASTUZUMAB EMTANSINE",
            "code": "SE2KH7T06F"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "SUCCINIC ACID",
            "code": "AB6MNQ6J6L"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Dosage and Administration (2.1) ]",
    "contraindications": "Do not substitute KADCYLA for or with trastuzumab. HER2 Testing: Perform using FDA-approved tests by laboratories with demonstrated proficiency. ( 2.1 ) For intravenous infusion only . Do not administer as an intravenous push or bolus. Do not use Dextrose (5%) solution. ( 2.4 ) The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity, or a total of 14 cycles for patients with EBC. Do not administer KADCYLA at doses greater than 3.6 mg/kg. ( 2.2 ) Management of adverse reactions (infusion-related reactions, hepatotoxicity, left ventricular cardiac dysfunction, thrombocytopenia, pulmonary toxicity or peripheral neuropathy) may require temporary interruption, dose reduction, or treatment discontinuation of KADCYLA. ( 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "None."
}